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Abstract. Estrogens secreted by the ovary during the pre/periimplantation period and/or by
the blastocyst and acting locally on the endometrium are involved in the initiation of
implantation. Estrogens induce a cascade of metabolic changes in the uterus and blastocyst
prior to and soon after the attachment and implantation of the blastocysts. Antiestrogens
either administered intraluminally into the uterus prior to implantation or washing free
blastocysts with antiestrogens prior to transfer to uteri of progesterone treated hamsters leads
to failure of implantation. A number of antiestrogens which inhibit fertility in the rats do not
interfere with implantation in the hamster and monkey when administered post-coitally.
However, Zuclomiphene administered during days 5–11 of the menstrual cycle inhibits
implantation in the rhesus monkey. Antiestrogens are being evaluated in other non-human
primates to confirm the above results and to determine the time in the menstrual cycle
susceptible to modification and inhibition of implantation. Tamoxifen administered from days
18–30 of the cycle to mated bonnet monkeys inhibited implantation despite maintenance of
high levels of circulating progesterone. Neutralization of the vitamin carrier proteins (by active
immunization against these proteins) interferes with established pregnancy in the rat and
perhaps in the bonnet monkey. Whether antiestrogens can reduce the levels of vitamin carrier
proteins to a level which is not adequate for maintenance of early pregnancy is not clear.
Compounds which show antiestrogenic and antiprogestational properties may have ad-
vantages in inhibiting implantation or disruption of early pregnancy. Critical experiments
need to be carried out in non-human primates to delineate the effectiveness of antiestrogens,
with particular emphasis on time, dose, duration and route of administration in inhibition of
implantation. Centchroman, an antiestrogen with antiprogestational properties, has been
found to provide pregnancy protection with minimal side effects. However, several concerns
relating to safety in toxicological studies in monkeys and a dose which would provide
acceptable rate of contraceptive efficacy without major effects on the menstrual cycle need to
be clarified before considering the potential of centchroman as a possible oral contraceptive
administered either post-coitally or once a week. Inhibition of implantation by administration
of tamoxifen opens up new possibilities of use of antiestrogens for fertility regulation.
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Introduction
 
The importance of the development of drugs which can be taken once-a-month or in
cases where there is a delay in the onset of menstrual cycles by 7–10 days is well
recognized. The availability of such technology would limit the exposure to fertility
regulating agents only to such occasions when there is the possibility of a pregnancy
(Prasad, 1983). Interruption of early pregnancy leading to the onset of menstrual
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bleeding or menstrual regulation could be achieved by one or more of the following
methods: blocking progesterone receptors and interference with the preparation of the
uterus for implantation or deprivation of the endometrium of progesterone required
for the maintenance of an established pregnancy in the immediate post-implantation
period [e.g. antiprogestins like RU-38486 presently being evaluated by the World
Health Organization (WHO), 1983]; induction of luteolysis leading to decreased
progesterone levels and interruption of early pregnancy [e.g. human chorionic
gonadotrophin (hCG) derivatives acting as hCG antagonists and blocking luteal
receptors: developed and evaluated by the WHO (1982)]; termination of early
pregnancy by prostaglandins (WHO, 1982, 1983); interference with the action of
estrogens on the fallopian tube/uterus in the post-coital period by treatment with
antiestrogens resulting either in the expulsion of the product of fertilization or
inhibition of implantation (e.g. Centchroman: Kamboj et al. 1977; Anordrin: Lei and
Hu, 1981). 
Attempts at the development of antiestrogens (estrogen antagonists) for interference
with implantation have not been successful so far. This review highlights the role of
estrogens in the initiation of implantation in mammals and possibilities of interfering
with implantation or termination of early pregnancy by estrogen antagonists which will
be referred to in this review by the commonly accepted terminology as “antiestrogens”.
 
Need for estrogen in implantation
 
The uterus is prepared for attachment and nidation of the blastocyst by sequential
action of estradiol secreted by the follicles before ovulation and by progesterone
secreted by the corpus luteum. Ovarian progesterone is always essential for the
preparation of the endometrium for the attachment of the blastocyst. Studies on the
hormonal requirements for implantation have shown that estrogens (estradiol) are
generally involved in the initiation of implantation in a number of mammalian species
(Psychoyos, 1973).
 
Rat and mouse
 
In the intact rat elevated estradiol levels on day 4 post-coitum permit the attachment
and implantation of the blastocyst (Psychoyos, 1973; Yoshinaga, 1976). In the rat
ovariectomised on day 3 post-coitum and treated with progesterone to delay
implantation the levels of endogenous progesterone are high; implantation occurs only
after exogenous administration of estrone or estradiol (Psychoyos, 1973). A local action
of estradiol administered to a small segment of the uterus permits implantation of the
blastocysts (during delayed implantation) at the site of injection of estrogen
(Yoshinaga, 1976). The role of ovarian estrogens in the initiation of implantation is
similar in the mouse (McCormack and Greenwald, 1974).
 
Hamster and rabbit 
 
Implantation occurs in the ovariectomized hamster only by the administration of
progesterone (Prasad et al., 1960; Harper et al., 1969). Progesterone is capable of
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inducing implantation in the post-coitally ovariectomized hamster by exerting its
effects on the uterus primed by the action of estradiol secreted during the
pre/periovulatory period (Prasad and Rath, 1974). There is an increase in plasma
estradiol by day 3 post-coitum but its role in implantation is not clear (Joshi and
Labhshetwar, 1972). While exogenous administration of estrogen is not essential for
implantation in the ovariectomized-progesterone treated hamster, a combination of
estrone or estradiol with progesterone increases the number of implantation sites
(Orsini and Psychoyos, 1965; Kwun and Emmens, 1974; Evans and Kennedy, 1980).
In the rabbit, as in the case of hamster, implantation occurs in the post-coitally
ovariectomized animals treated with progesterone only; however, the number of
embryos implanting increase with the addition of estradiol (Kwun and Emmens, 1974).
 
 
Primates 
 
A limited amount of information is available on endocrine changes associated with
implantation in primates. The requirement of ovarian progesterone for implantation
was demonstrated by the failure of implantation in pregnant monkeys after ovariec-
tomy (Meyer et al., 1969) or lutectomy on day 6 post-coitum (Bosu and Johnsson,
1975). Meyer et al. (1969) successfully maintained pregnancy in 7 of 10 rhesus monkeys
ovariectomized on day 6 of gestation and treated with 5 or 50mg/kg/day of
progesterone from the day of ovariectomy until parturition. While these studies
demonstrate the requirement of progesterone for implantation in the rhesus monkey,
the requirement of ovarian estrogen for implantation is less clear. The fact that
pregnancy occurs in the ovariectomized-progesterone treated monkey indicates that
implantation occurs in the absence of estrogens, in a manner similar to that in the
hamster. It is likely that priming of the uterus by estrogens secreted during the
periovulatory period is adequate to permit implantation in the progesterone treated
monkeys. The issues that remain to be clarified relate to the role of estrogen in the
preimplantation period (days 1–5 post-coitum). Patterns of circulating estradiol 17 b
(E2) or total estrogen (E) during the periimplantation period (in the early luteal phase)
have been described in five primate species. A gradual increase in the levels of E2 occurs
in the preimplantation period in the fertile and infertile cycles of the rhesus monkey,
bonnet monkey (Anandkumar et al., 1980; Murthy et al., 1980; Rao and Moudgal, 1984;
Hendrickx and Enders, 1980); chimpanzee and stump tailed macaque (Hearn, J. P.
personal communication), and marmoset (Hearn, 1978), with a profile similar to that
seen in women (Thomas et al., 1973). There is no proof for the involvement of estradiol
in implantation in any non-human primate, neither is there any evidence to the
contrary; tonic levels may be quite sufficient for implantation to occur as in the case of
the hamster. 
 
 
Role of estrogen derived from the blastocyst in implantation
 
Preimplantation blastocysts of several mammals synthesize estrogens in vitro. In the
rat, mouse and hamster, steroidogenic capacity of the blastocyst was demonstrated by
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the presence of 3ß-17 ß-OH steroid dehydrogenases before implantation (Dickman
and Sen Gupta, 1974; Wu and Liu, 1982). Hamster blastocysts synthesize estradiol from
steroid precursors (Sholl et al., 1983). Dickman et al. (1977) proposed that estrogen
secreted by the blastocysts may be necessary for embryonic differentiation and
initiation of implantation and could play a role in maternal recognition of the
blastocyst during the attachment phase of implantation (Dickman et al., 1977). In
species like the hamster which has been shown to be dependent on progesterone alone
for implantation (Prasad et al., 1960), blastocyst estrogen may also be involved in the
initiation of implantation; injection of an estrogen antagonist (CI-628) at a dose of 5 µg
into the uterine horns of intact ovariectomized females receiving progesterone post-
coitally prevents implantation as does incubation of the blastocysts with the
antiestrogen before their transfer to the uterus of ovariectomized hamsters treated
with progesterone (Sen Gupta et al., 1983). These results show that while preovulatory
ovarian estradiol primes the uterus, estradiol produced by the blastocyst may also be
involved in initiating implantation; this is further substantiated by the observation that
progesterone alone permits implantation in hamsters ovariectomized and adrenalecto-
mised post-coitum to eliminate any extraovarian source of estrogen (Evans and
Kennedy, 1980). It is also likely that the endometrium may regulate the local
concentration of estrogens by 17ß-hydroxysteroid dehydrogenase permitting estradiol
17β → estrone conversion and by a sulphotransferase-sulphatase system which allows
estrogen sulphate  estrogen interconversion (Kreitman and Bayard, 1981; Woman:
Gurpide and Marks, 1980; Satyaswaroop et al., 1982; Rhesus: Kreitman et al., 1980;
Utaaker and Stoa, 1980; hamster: Legault et al., 1980; Tseng and Lin, 1981; Clark et al.,
1982). However, there are no data to relate the endometrial estrogen synthesis with
events leading to the initiation and maintenance of implantation.
 
 
 
 
Role of estrogen in implantation: Mechanism of action
 
Estradiol was shown to be involved in one or more of the following events in
implantation: embryonic development (Roy et al., 1982); spacing of blastocysts in the
uterine horns (Pope et al., 1982); increase of blood flow and capillary permeability
(Psychoyos, 1973); changes in uterine secretions (Aitken, 1977); regulation of prosta-
glandin synthesis at the time of implantation (Psychoyos, 1984); induce nucleic acid and
protein synthesis in the uterus and blastocyst (Mohla et al., 1970; Mohla and Prasad,
1971); stimulate mitotic divisions in the epithelial cells in the ovariectomized-hormone
starved uterus of the rat and hamster while estradiol initiates mitosis in the uterine
stroma and gland cells after treatment with progesterone (Martin and Finn, 1971; Tachi
et al., 1972; Prasad and Rath, 1974); and induce increase in adenyl cyclase and cyclic
AMP (Szego and Davis, 1967). 
Most of the studies on the mechanism of action of estradiol were carried out in
ovariectomized rat and mice treated with estrogen alone; this is not comparable to the
condition in the intact animal at the time of implantation where estradiol modulates the
activity of the progesterone primed uterus.
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Antiestrogens
 
Chemistry 
 
A number of steroidal and non-steroidal antiestrogens were studied for their
antifertility action in laboratory rodents and primates (Giannina et al., 1971; Prasad
and Sankaran, 1975; Harper, 1982 for detailed review). Anti-estrogens are diverse in
their chemical structure although all the compounds with the exception of U-11634 are
basically estrogenic. They show marked variations in the degree of estrogenicity and
antiestrogenicity.
 
 
 
Mechanism of action
 
The current concepts on the mode of action of antiestrogens may be summarized as
follows. These generalizations are based on review of the literature cited by Prasad and
Sankaran (1975) and some selected recent studies (Liberman et al., 1983; Sutherland et
al., 1980; Sudo et al., 1980; Eckert and Katzellenbogen, 1981; Katzellenbogen et al.,
1984; Murthy and Sutherland, 1981; Markaverich and Clark, 1981; Furr and Jordan
1984). The list of references on mechanism of action of antiestrogens is too long to be
cited in full. 
(a) Antiestrogens inhibit the action of estrogens either in their original molecular form
or through their metabolites by influencing: (i) the metabolism, transport and eventual
entry of estrogens to the target cells; (ii) the uptake of estrogens by the cytoplasmic
hormone receptors; (iii) the transport of the cytoplasmic receptor-hormone complex
to the nucleus as the nuclear receptor; (iv) the interaction between the nuclear receptor
and nuclear acceptor; and (v) the transcriptional and translational steps in estrogen
action.
(b) Estrogens and antiestrogens are mutully competitive for binding to saturable
estrogen receptor binding sites in the target tissues. However, high affinity binding sites
may have a role in regulating the effects of non-steroidal antiestrogens.
(c) Antiestrogens differ from one another in their dynamics of interaction with the
estrogen receptors and in their ability to stimulate increase in cellular progesterone
receptor. Apparently complex relationships exist between the number of receptors and
the duration of the presence of the hormone receptor complexes in the nucleus.
(d) Cell growth and progesterone receptor induction may be modulated by
antiestrogens. 
(e) The antiestrogenicity of a compound is proportional to the affinity of binding to the
cytoplasmic estrogen/antiestrogen receptor and also its intrinsic ability to transfer the
receptor complex into the nucleus. 
(f) Triphenylethylene compounds bind to a saturable binding site distinct from the
estrogen receptor. The significance and subcellular role of this component needs to be
defined before speculating on its function.
(g) Heterogeneity of nuclear estrogen receptors are implicated in the action of
estrogens. Low abundance of nuclear Type II binding sites is a feature of antiestrogens
but this hypothesis needs further verification.
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(h) The degree of antiestrogenicity of a compound is generally proportional to its
inherent estrogenicity.
(i) Some antiestrogens retain their antiestrogenicity for prolonged periods of time
following a single administration. This reflects the long biological half life of the
compound, high level of binding to plasma proteins and enterohepatic circulation.
 
Antifertility action
 
Antifertility action of a number of antiestrogens evaluated in several species is shown in
table 1. 
 
Table 1.  Post-coital antifertility efficacy of nonsteroidal antiestrogens.
 
 
(+) Effective; (–) ineffective. For details of description of compounds and structures See Prasad and
Sankaran (1975); anordrin (Lei and Hu, 1981).
 
The antiimplantation action of antiestrogens administered post-coitally may be due
to one or more of the following mechanisms (Prasad and Sankaran, 1975): (i) the
compounds may increase tubal motility due to their estrogenic activity resulting in the
expulsion of the blastocysts (MER-25; DMS; Clomiphene; U-11100A U-11555A, DBF,
Centchroman); (ii) the compounds may be cytotoxic and affect the viability of the
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blastocysts (MER-25); (iii) they may inhibit the uptake of estrogens and subsequently
the action of estrogen on the target organs (MER-25; Clomiphene; CN-55945-27;
Centchroman); (iv) by their antihistaminic activity, they may inhibit decidual cell
response by blocking estrogen-dependent enzyme activities (MER-25) or estrogen
dependent protein synthesis prerequisite to the preparation of the uterus for
implantation (U-11634); (v) the compounds may cause luteolysis through the stimu-
lation of pituitary LH; the lowered progesterone level then intereferes with implant-
tation (CN-55945-27). 
Although the mode of action of antiestrogens in interfering with implanation in the
rat and mouse is clear, their action in other species like the hamster and non-human
primates is as yet unclear. Antiestrogens which are effective in inhibiting in the rat are
ineffective when administered post-coitally in the hamster (Duncan et al., 1966) and
rhesus monkey (Morris et al., 1967; Segal et al., 1972). It is to be noted that in both these
species progesterone alone permits implantation which is possibly facilitated by the
local action of estrogen produced by the blastocyst in the hamster. The failure to inhibit
implantation in these species may be due either to the inappropriate timing and dose of
the antiestrogens administered or their inability to reach the uterine milieu in adequate
concentrations to interfere with the action of estrogen produced by the blastocyst and
acting on the uterus locally at the site of implantation.
 
 
Critical phases in reproduction vulnerable to interference with antiestrogens
 
The critical and crucial events in reproduction in the female nonhuman primate that
can lead to inhibition of implantation or disruption of an established implantation by
administration of antiestrogens are: (a) Inhibition of luteal function, (b) Inhibition of
estrogen mediated changes in the endometrium, the estrogen being derived either from
the ovary, or by synthetic activity of the blastocyst and /or endometrium. There is no
evidence to show that the monkey or human blastocyst produces estrogen,
(c) Estrogen antagonism on progesterone production in early pregnancy. (d) Interfere
with estrogen-induced synthesis of vitamin carrier proteins involved in the trans-
placental transfer of vitamins essential for the survival and growth of the foetus.
 
 
Inhibition of luteal function
 
In the rhesus monkey, the elevation in progesterone levels of the fertile cycle, termed as
the ‘rescue’ of the corpus luteum is due to a luteotrophic stimulus originating in the
implanting blastocyst. The chorionic gonadotrophin secreted by the blastocyst can be
detected in the peripheral blood or urine earliest on day 9–10 of pregnancy in the rhesus
or bonnet monkey (Atkinson et al., 1975; Hendrickx and Enders, 1980; Murthy er al.,
1980). Treatment with antiestrogens which leads to interference with mechanisms
rescuing the corpus luteum resulting in a decline in progesterone levels required for the
initiation and maintenance of implantation would be an attractive approach to regulate
fertility. This needs to be evaluated in different non-human primates.
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Inhibition of implantation
 
Hendrickx and Sankaran, (personal communication) have reported inhibition of
implantation in 4 out of 5 rhesus monkeys by administration of zuclomiphene
(2 mg/kg/day) for seven days on days 5–11 of the menstrual cycle; the antiestrogen did
not have any effect on the normal levels of hormones in the peripheral blood and
ovulation at this dose. Through the mechanism/s of action of zuclomiphene in
inhibiting implanation are not clear, it is possible that the compound, due to its
antiestrogenic properties, might have inhibited the action of periovulatory estrogens
resulting in subnormal progestational action and impairment of implantation of the
blastocyst. These studies demonstrate, though not conclusively, the role of peri-
ovulatory estrogens and offer an experimental model for studies on interactions of 
hormones during the periimplantation period of early pregnancy in non-human
primates. Similar studies are being carried out in the bonnet monkey (Moudgal, N. R.,
personal communication). It would be of interest to determine if antiestrogens
administered on specific days during the preovulatory period of the non-human
primates would induce luteal insufficiency and other luteal defects (short luetal phase)
in a manner similar to that caused by selective inhibition of follicle stimulating
hormone during this period. 
Moudgal (personal communication) has shown that administration of 3 mg/kg/day
of Tamoxifen on days 18–30 to bonnet monkeys (following successful mating in an
ovulatory cycle) resulted in interference with implantation and establishment of
pregnancy in 9 of the 10 treated animals; menstrual cycles occurred in these monkeys on
days 23–29 despite maintenance of high levels of progesterone comparable to those in
pregnant monkeys. Concurrent administration of Depot Medroxy progesterone
acetate did not reverse effects of tamoxifen. The mechanism of action of tamoxifen in
interfering with implantation is not clear. The action of tamoxifen could be sought for
in its possible direct effects on the uterus in inhibiting the action of progresterone on the
uterus either by modifying the endometrial progesterone receptors or expression of
metabolic responses to progesterone and preparation of the uterus for implantation.
These results which demonstrate the antiimplantation effect of tamoxifen are of
considerable interest and open up new possibilities of use of antiestrogens for fertility
regulation. Clinical trials need to be carried out to assess the antiimplantation effect of
tamoxifen by administering the drug at different time periods in the mestrual cycle.
Since tamoxifen is used extensively in the treatment of breast cancer in women, there
should be no difficulty in the initiation of clinical trials.
 
 
Effect of antiestrogen on progesterone production during pregnancy
 
Treatment of baboons with MER-25 in the last trimester of pregnancy results in a
decline in plasma progesterone without any effects on the clearance of progesterone
(Albrecht, 1980). Since there was no effect on progesterone levels during the luteal phase
of the non-pregnant baboons, the effect on the pregnant animals was presumed to
indicate a role for progesterone in placental progesterone production and its inhibition
by the antiestrogen MER-25. Oral administration of MER-25 to pregnant baboons on
 
Role of antiestrogens in the regulation of fertility 169
 
days 35–55 after conception results in a decline in the peripheral plasma levels of
progesterone within a few days and persists for at least 20 days without any effects on
plasma estradiol levels (Castracane et al., 1983).
Administration of 15 mg/kg of MER-25 or enclomiphene citrate throughout the
luteal phase of the menstrual cycle did not have any effects on the maintenance of the
corpus luteum, length of the cycle, and levels of serum progesterone, 17 hydroxy
progesterone or estradiol (Albrecht et al., 1984). The decline in progesterone
production in animals treated with MER-25 may reflect reduction in the function of the
placenta but not of the corpus luteum. Even though the progesterone levels were
decreased in these baboons treated with MER-25, pregnancy was maintained which
may be due to the circulating levels of progesterone being still adequate to maintain
pregnancy. Similar studies need to be carried out in other non-human primates. The
marmosets which have very high levels of progesterone during pregnancy may not be
suitable animal models for such studies.
 
 
Interference with estrogen-induced vitamin carrier proteins in pregnancy
 
Adiga and Murthy (1983) have shown that specific vitamin carrier proteins for
riboflavin and thiamin in the rat are estrogen-induced gene products of hepatic origin.
These proteins are essential for the transplacental transport of the vitamins essential for
the maintenance of the viability of the foetus. Interference with the vitamin carrier
proteins by active or passive immunization against these proteins leads to the
termination of pregnancies without any deleterious effects on the vitamin status of the
pregnant animal or its subsequent fertility. Sheshagiri et al. (1984) have also shown that
maximum levels of the vitamin carrier proteins in circulation occur in the bonnet
monkey on days 16–18 of the menstrual cycle, i.e. 3–4 days after the preovulatory surge
of estrogen; similar proteins have been demonstrated in the bonnet monkeys and in
human pregnancy serum in the cord blood. Immunological neutralization of the
vitamin carrier proteins in the pregnant bonnet monkey led to the termination of
pregnancy. Recent studies presented at the Indo-US Workshop on Blastocyst
Research, Seshagiri et al. (1984) showed that in the female bonnet monkeys of proven
fertility, active immunization with the chicken riboflavin and thiamin-carrier protein
did not interfere with their general health, cyclicity, hormonal profile or vitamin status;
when mated during the fertile cycles such actively immunized animals with high titres of
antibody against the vitamin carrier proteins rejected their foetuses. These results are of 
interest and need further amplification in specifying (a) whether the vitamin carrier
proteins are critical during the pre/periimplanatation period and (b) the role of
antiestrogens in inhibition of induction of the vitamin carrier proteins by endogenous
estrogens and consequent effects on pregnancy. These studies need to be carried out
with other antiestrogens like Centchroman. Problems that are inherent in the design of
a study to specify the role of antiestrogens in inhibiting implantation are: the choice of
antiestrognes, dose, route of administration and duration of treatment; since the
vitamin carrier proteins are essential for maintenance of pregnancy, termination of
pregnancy resulting from antiestrogen treatment should be complete and 100%
effective. Acceptance of the approach as a method of fertility regulation would depend
 
170 Prasad
 
on its safety and efficacy being better than the currently available methods for the
termination of early pregnancy.
 
 
Compounds with antiestrogenic and antiprogestational action
 
Recent studies have highlighted interest in an antiprogestational compound, RU-38486
which is being evaluated clinically for termination of very early pregnancy (WHO,
1983); the compound apparently acts by blocking endometrial progesterone receptors
to disrupt early pregnancy; preliminary results seem to indicate that the drug, even in
high doses, may not result in complete evacuation of the product of conception from
the uterus. In the light of recent studies by Adiga and Murthy (1983) on the role of
estrogen-induced vitamin carrier proteins in the maintenance of pregnancy, it is of
interest to consider the possibility of evaluating compounds which show both
antiestrogenic and antiprogestational activities. 
Centchroman (trans-2,2-dimethyl-3-phenyl-1-4-(p-b-pyrrolidoneethoxyphenyl)-7-
methoxy chroman hydrochloride) (see Prasad, 1983 for structure), developed by the
Central Drug Research Institute, Lucknow, India, has weak estrogenic and anti-
estrogenic activity; its antifertility activity in rats and monkeys may be due to its
multiple attributes such as weak estrogenic, antiestrogenic and antiprogestational
activities (Kamboj et al., 1977). The activity profile of Centchroman is as follows:
antiimplantation activity in rats, dogs and monkeys; weak estrogen and potent
antiestrogen; interferes with progesterone action (in induction of deciduomata in rats,
inhibition of progesterone induced delayed implantation in rats, Clauberg Assay,
inhibition of exogenously administered progesterone); no effects on adrenal, thyroid
and pituitary function; pharmacologically inert at contraceptive dose; no teratogenicity
(mice-rabbit) or mutagenicity; safe in chronic toxicity evaluation in rat and rhesus
monkey; good therapeutic ratio (> 1800); safe in Phase I clinical studies; dose range 
evaluation in weekly regimen completed; currently under Phase II clinical trial as a
30 mg/weekly oral pill; effective against 40 % of stage four breast cancer patients.
Phase II clinical trials have been carried out in post-coital (60 mg) and once-a-week
treatment schedules at doses of 120, 60 and 45 mg. The results reported indicate that
Centchroman provides good protection against pregnancy at all doses studied
(Nityanand, personal communication); ovarian and uterine enlargement was observed
in all treatment regimes, with recovery to normal size within 30 days of the withdrawl of
drug treatment. Delay in menstruation of varying duration has also been reported.
Since these high doses led to ovarian/uterine enlargement and irregular menstrual cycles,
further clinical evaluation was carried out with 30 mg/week; data involving 368
subjects indicate acceptable pregnancy protection with minimal side effects and delay
in the menstrual cycles of 10% of the treated subjects (Nityanand, personal communi-
cation). High priority in such studies is to determine a dose which will provide a high
degree of protection against pregnancy without effects on the menstrual cycle and
ovarian/uterine functions. Questions have also been raised by the drug regulatory
agencies on the acceptability of some of the toxicology data. The Central Drug
Research Institute has apparently carried out once again a one-year toxicity evaluation
of Centchroman and has initiated life term studies. Should these new toxicology and
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clinical data be considered satisfactory by the toxicology review panel of the Indian
Council of Medical Research and the Drug Regulatory Authority in India, a case
could be made for further clinical evaluation of Centchroman which has the advantage
of possessing antiestrogenic and antiprogestational properties. A number of years have
elapsed since claims were made that Centchroman, developed solely by an Indian
laboratory would be available as a post-coital or weekly pill for regulation of fertility. It
is time that concerted efforts are made to evaluate all the available clinical and
toxicological data to determine the potential of Centchroman as a fertility regulating
agent for introduction in the National Family Welfare Programme in India.
 
Anordrin 
 
Anordrin has been used in the Peoples Republic of China as a post-coital pill at a dose
of 7·5 mg (Lei and Hu, 1981). The drug apparently interferes with implantation by
inhibiting luteal function and endometrial development. It is not clear from the Chinese
studies if anordrin was ever used strictly as a post-coital pill. The antifertility action of
Anordrin has been attributed to its antiestrogenic activity (Mehta et al., 1981), or to its
estrogenic acceleration of tubal transport or degeneration of eggs during tubal
transport in the hamster (Gu et al., 1975; Gu and Chang, 1979).
A number of attempts have been made to synthesize related compounds to dissociate
estrogenic activity from antifertility effects. Crabbe et al. (1979) reported the synthesis
and biological evaluation of 2α anordrin and its corresponding diproprionate,
dinordrin I (2α, 17α-diethynyl-A-nor-5α-estrane-2ß-17-ß-diol) and the 2β epimer,
dinordrin II (see Prasad, 1983 for structures of the two compounds). Dinordrin I was
20 times more potent than anordrin or dinordrin II. Both anordrin and dinordrin I
showed antifertility effect in rats and were luteolytic in baboons; the antifertility activity
generally paralleled uterotrophic activity (estrogenic activity). Chinese scientists have
synthesized derivatives of anordrin and dinordrin and its epimers by total synthesis in
an attempt to separate the estrogenic from antifertility activities (WHO, 1983).
A number of steroidal and non-steroidal compounds that showed promise as post-
coital antifertility agents have been evaluated in animals in an attempt to identify an
effective drug having little estrogenic activity but with enhanced antiestrogenic activity, 
but none has reached phase III or IV clinical trials (Giannina et al., 1971; Prasad and
Sankaran, 1975; Harper, 1982). Centchroman has been evaluated as a once-a-week pill
and found to be effective. Inhibition of implantation by tamoxifen in bonnet monkey
opens up new possibilities of use of another antiestrogen for fertility regulation.
Clinical trials need to be carried out to assess the efficacy of tamoxifen in interfering
with implantation in women.
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